Background: A close relationship between rheumatic diseases and cardiovascular disease (CVD) has been reported, accounting for the higher mortality and morbidity observed in these patients. In the last years, it has been clearly reported that patients affected by primary Sjogren’s syndrome (pSS) experienced an increased risk of CVD. Objective: This review aimed at investigating CVD, traditional cardiovascular (CV) risk factors and possible targeted therapeutic strategies in pSS patients. Method: Available literature concerning CV risk factors in pSS patients has been selected and discussed. Conclusion: Disease-related characteristics and traditional CV risk factors contribute to observed atherosclerotic damage in pSS patients. The pro-inflammatory mediators together with hypertension and type 2 diabetes, which are more prevalent in pSS patients, determine the increased CV burden. Future studies are needed to fully elucidate the role of possible targeted therapies.
Berardicurti O., Ruscitti P., Cipriani P., Ciccia F., Liakouli V., Guggino G., et al. (2018). Cardiovascular disease in primary sjögren’s syndrome. REVIEWS ON RECENT CLINICAL TRIALS, 13(3), 164-169 [10.2174/1574887113666180315130336].
Cardiovascular disease in primary sjögren’s syndrome
Ciccia F.;Guggino G.;
2018-01-01
Abstract
Background: A close relationship between rheumatic diseases and cardiovascular disease (CVD) has been reported, accounting for the higher mortality and morbidity observed in these patients. In the last years, it has been clearly reported that patients affected by primary Sjogren’s syndrome (pSS) experienced an increased risk of CVD. Objective: This review aimed at investigating CVD, traditional cardiovascular (CV) risk factors and possible targeted therapeutic strategies in pSS patients. Method: Available literature concerning CV risk factors in pSS patients has been selected and discussed. Conclusion: Disease-related characteristics and traditional CV risk factors contribute to observed atherosclerotic damage in pSS patients. The pro-inflammatory mediators together with hypertension and type 2 diabetes, which are more prevalent in pSS patients, determine the increased CV burden. Future studies are needed to fully elucidate the role of possible targeted therapies.File | Dimensione | Formato | |
---|---|---|---|
Onorina Berardicurti RRCT MS.pdf
Solo gestori archvio
Tipologia:
Altro materiale (es. dati della ricerca)
Dimensione
212.92 kB
Formato
Adobe PDF
|
212.92 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.